Tissue | Expression Dynamics | Abbreviation |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/PCOLCE_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PCOLCE_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PCOLCE_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PCOLCE_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PCOLCE_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004586216 | Endometrium | AEH | positive regulation of proteolysis | 81/2100 | 372/18723 | 2.72e-09 | 2.06e-07 | 81 |
GO:005254716 | Endometrium | AEH | regulation of peptidase activity | 85/2100 | 461/18723 | 2.47e-06 | 7.11e-05 | 85 |
GO:001095216 | Endometrium | AEH | positive regulation of peptidase activity | 44/2100 | 197/18723 | 5.53e-06 | 1.38e-04 | 44 |
GO:004586217 | Endometrium | EEC | positive regulation of proteolysis | 83/2168 | 372/18723 | 2.32e-09 | 1.86e-07 | 83 |
GO:005254717 | Endometrium | EEC | regulation of peptidase activity | 91/2168 | 461/18723 | 2.00e-07 | 8.93e-06 | 91 |
GO:001095217 | Endometrium | EEC | positive regulation of peptidase activity | 44/2168 | 197/18723 | 1.25e-05 | 2.54e-04 | 44 |
GO:0045862111 | Esophagus | ESCC | positive regulation of proteolysis | 256/8552 | 372/18723 | 7.88e-20 | 9.43e-18 | 256 |
GO:0010952111 | Esophagus | ESCC | positive regulation of peptidase activity | 133/8552 | 197/18723 | 4.31e-10 | 1.14e-08 | 133 |
GO:0052547111 | Esophagus | ESCC | regulation of peptidase activity | 275/8552 | 461/18723 | 7.54e-10 | 1.88e-08 | 275 |
GO:004586212 | Liver | Cirrhotic | positive regulation of proteolysis | 163/4634 | 372/18723 | 4.18e-16 | 5.14e-14 | 163 |
GO:005254712 | Liver | Cirrhotic | regulation of peptidase activity | 185/4634 | 461/18723 | 1.32e-13 | 1.09e-11 | 185 |
GO:00109527 | Liver | Cirrhotic | positive regulation of peptidase activity | 81/4634 | 197/18723 | 2.89e-07 | 7.03e-06 | 81 |
GO:004586222 | Liver | HCC | positive regulation of proteolysis | 232/7958 | 372/18723 | 5.66e-15 | 3.98e-13 | 232 |
GO:005254722 | Liver | HCC | regulation of peptidase activity | 247/7958 | 461/18723 | 8.28e-07 | 1.27e-05 | 247 |
GO:001095212 | Liver | HCC | positive regulation of peptidase activity | 110/7958 | 197/18723 | 1.04e-04 | 8.98e-04 | 110 |
GO:005254727 | Skin | AK | regulation of peptidase activity | 88/1910 | 461/18723 | 4.65e-09 | 3.44e-07 | 88 |
GO:004586228 | Skin | AK | positive regulation of proteolysis | 74/1910 | 372/18723 | 1.32e-08 | 8.20e-07 | 74 |
GO:001095226 | Skin | AK | positive regulation of peptidase activity | 39/1910 | 197/18723 | 3.82e-05 | 6.31e-04 | 39 |
GO:0045862112 | Skin | SCCIS | positive regulation of proteolysis | 43/919 | 372/18723 | 1.69e-07 | 1.91e-05 | 43 |
GO:0052547112 | Skin | SCCIS | regulation of peptidase activity | 46/919 | 461/18723 | 4.09e-06 | 1.82e-04 | 46 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PCOLCE | SNV | Missense_Mutation | novel | c.470N>T | p.Gln157Leu | p.Q157L | Q15113 | protein_coding | deleterious(0) | benign(0.342) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PCOLCE | SNV | Missense_Mutation | | c.1179N>T | p.Lys393Asn | p.K393N | Q15113 | protein_coding | deleterious(0.01) | possibly_damaging(0.89) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
PCOLCE | SNV | Missense_Mutation | novel | c.10N>A | p.Ala4Thr | p.A4T | Q15113 | protein_coding | tolerated_low_confidence(0.21) | benign(0.001) | TCGA-AP-A1DR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
PCOLCE | SNV | Missense_Mutation | novel | c.937N>G | p.Pro313Ala | p.P313A | Q15113 | protein_coding | tolerated(0.07) | benign(0.005) | TCGA-AX-A1CA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
PCOLCE | SNV | Missense_Mutation | | c.139N>C | p.Tyr47His | p.Y47H | Q15113 | protein_coding | deleterious(0) | possibly_damaging(0.793) | TCGA-B5-A0JV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
PCOLCE | SNV | Missense_Mutation | | c.736T>C | p.Ser246Pro | p.S246P | Q15113 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-BS-A0UJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PCOLCE | SNV | Missense_Mutation | novel | c.318N>C | p.Gln106His | p.Q106H | Q15113 | protein_coding | deleterious(0.02) | benign(0.363) | TCGA-D1-A16F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PCOLCE | SNV | Missense_Mutation | novel | c.802N>A | p.Ala268Thr | p.A268T | Q15113 | protein_coding | deleterious(0) | possibly_damaging(0.838) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PCOLCE | SNV | Missense_Mutation | rs747502040 | c.353N>T | p.Ala118Val | p.A118V | Q15113 | protein_coding | deleterious(0.02) | benign(0.067) | TCGA-EY-A1GU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PCOLCE | SNV | Missense_Mutation | novel | c.281N>T | p.Ala94Val | p.A94V | Q15113 | protein_coding | tolerated(0.12) | benign(0.348) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |